Marathon Trading Investment Management’s SELLAS Life Sciences SLS Stock Holding History

Marathon Trading Investment Management’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.04K	Buy	+1,191	New	+$5.33K	﹤0.01%	262

Other funds holding SLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Marathon Trading Investment Management's SLS Position: Q1 2026 in Review

Marathon Trading Investment Management opened a new position in SELLAS Life Sciences (SLS) in Q1 2026: 1,191 shares worth $5.04K. The stake represents ﹤0.01% of the portfolio and ranks #262 among its holdings.

160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

Marathon Trading Investment Management held 1,191 shares of SELLAS Life Sciences worth $5.04K as of Q1 2026.
SELLAS Life Sciences was a new Marathon Trading Investment Management position in Q1 2026.
SELLAS Life Sciences made up ﹤0.01% of Marathon Trading Investment Management's portfolio in Q1 2026, its #262 holding.
160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Marathon Trading Investment Management's 13F filing for Q1 2026, filed 14 May 2026.